Xiidra has
~90% overall coverage

for commercial and Medicare Part D patients nationwide1*

Check sign icon
Commercial

Xiidra coverage exceeds Restasis® in most major plans1†

Dollar sign icon
Pay as little as $0

With Xiidra, eligible commercial patients may pay $0 for their first Rx2‡

Plus sign icon
Medicare Part D

Xiidra offers equal coverage to Restasis® in most major plans3

We've got you and your patients covered

ELIGIBLE COMMERCIAL Patients may
pay as little as
Zero dollars

When using the Xiidra Co-pay Card, ~90% of eligible commercial patients paid $02‡

dollar sign icon
Is your patient experiencing financial hardship?

For patients who have limited or no prescription coverage, contact 1-877-4XiiDRA (1-877-494-4372) or visit www.patientassistance.bausch.com. Patients who are eligible may receive their medication for free

question mark icon
Additional questions about cost and affordability?

For more on helping patients start and stay on Xiidra, and information on Xiidra's $0 Co-Pay Program for commercially eligible patients or the Insider Support Program, please call the Xiidra Access Program at 1-877-4XiiDRA (1-877-494-4372)

There are additional ways to help patients save

Xiidra Rx in a link

BlinkRx assists with prior authorizations and more, offering a seamless experience for your practice and patients

 thumbs up icon
Prior Authorization Support

BlinkRx services provide prior authorization support for Xiidra prescriptions, should your patients’ insurance require it

money icon
Low Price

BlinkRx works with your eligible commercially insured patients’ insurance and applies available savings to their Xiidra prescription, with no co-pay card needed

  lightning icon
Free and Fast Delivery

BlinkRx delivers Xiidra prescriptions for free from one of their licensed network pharmacies around the country

 mobile phone icon
Simple Patient Experience

BlinkRx will send patients a text with the lowest available price so that they can immediately purchase their Xiidra prescription online or over the phone

Ample Stocking

BlinkRx services the entire country, making Xiidra accessible for all patients

Dedicated Customer Support

BlinkRx has a team of pharmacists and technicians that are available to support you, your team, and your patients from onboarding to adherence

Want to learn more about BlinkRx?

Find a helpful guide and additional downloadable resources

Need Prior
Authorization Support?

Being proactive in the prior authorization process may help improve your patients’ success with Xiidra

Help Patients Start and Stay on Xiidra

Send patients home with the materials they need for a smooth onboarding process

*Based on data from April 2024. Up to 95% of commercial and 71% of Medicare Part D patients may be covered.

Plan limitations may apply.

Terms and conditions apply. For the first 30-day, 60-day, or 90-day prescription. Subject to benefit limitations. Visit Xiidra.com for complete terms and conditions.

CONNECT WITH US

CONNECT WITH US

By submitting your information, you consent to receive communications containing information and educational resources about Xiidra, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

By submitting your information, you consent to receive communications containing information and educational resources about Xiidra, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

Indication and important safety information

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for Xiidra.

References

  • Data on file. MMIT Portal, April 2024. Bausch & Lomb Inc.
  • Data on file. ConnectiveRx Xiidra Savings Card Co-pay as of 2024. Bausch & Lomb Inc.
  • Data on file. MMIT Portal, February 2024. Bausch & Lomb Inc.

Indication and important safety information

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced